{
  "docId": "019dd923-622c-750b-8b9a-2a2468219173",
  "docSlug": "ce565b841c40",
  "documentTitle": "Nevro Corp. (NVRO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Kir Kahlon",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2021-01-07 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 62,
  "pageCount": 239,
  "prevPage": 61,
  "nextPage": 63,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "Uses red circles to highlight specific names and study titles to draw attention to the contradiction.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "screenshot",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-2a2468219173/62",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173#slide-62",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.51,
        "y": 0.46
      },
      "kind": "callout",
      "text": "Adnan Al-Kaisy said he had switched over to Nevro and then he started seeing what you've noted. He had seen 20 to 30 patients with no sustained benefit. He was seeing explants. So he started spreading his business around. He didn't bash Nevro completely. But he's gotten to a point where he thinks other devices like Boston Scientific are a better option.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2a77d4e6-6797-48dc-b5ff-83bcb9435447",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "callout",
      "text": "The sheen is off Nevro. I've known [Nevro senior executive] for [redacted] years. I don't know that he's the right guy. I wouldn't buy stock in Nevro right now. Their story is getting stale.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b33b-2e47a924f697",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.88,
        "x": 0.06,
        "y": 0.13
      },
      "kind": "paragraph",
      "text": "He concluded his already devastating comments by stating that a UK-based KOL saw no sustained benefit from Nevro's high frequency either and preferred other devices – and that Nevro was now a stale story in which he wouldn't buy stock. Comically, this UK doctor was the lead author on Nevro's key European 24 month HF study – the US equivalent of the SENZA-RCT pivotal trial. His study is the first that Nevro cites on the “Clinical Evidence” page of its site. This European study and the US SENZA-RCT are Nevro's two 24-month outcomes studies - the foundation upon which Nevro's high frequency's claims rest. Deep skepticism of Nevro's study from one and apparent skepticism by the other is telling.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c6c3d66f-4351-4104-bd07-35c6aa65f7f2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.06,
        "y": 0.52
      },
      "kind": "paragraph",
      "text": "Sustained effectiveness of 10 kHz high-frequency spinal cord stimulation for patients with chronic, low back pain: 24-month results of a prospective multicenter study",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dbf84f3d-2979-41e5-9e23-e014e07e2501",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.51,
        "y": 0.73
      },
      "kind": "quote",
      "text": "“Nevro came out with something new and got a lot of share in a crowded space. The sheen is off Nevro. I've known [Nevro senior executive] for [redacted] years. I don't know that he's the right guy. I wouldn't buy stock in Nevro right now. Their story is getting stale.” – KOL and key player in the SENZA-RCT pivotal trial",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9d8822ac-70b2-4ef2-bb1d-3df3b2e2b1b6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.51,
        "y": 0.63
      },
      "kind": "quote",
      "text": "[Doctor name redacted] in my state switched over completely to Nevro. Then he had issues with Nevro. I think he switched away again.",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9fa99459-3e4a-4ee6-a3f0-2635c423a20c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "Adnan Al-Kaisy said he had switched over to Nevro and then he started seeing what you've noted. He had seen 20 to 30 patients with no sustained benefit. He was seeing explants. So he started spreading his business around. He didn't bash Nevro completely. But he's gotten to a point where he thinks other devices like Boston Scientific are a better option. — KOL and key player in the SENZA-RCT pivotal trial",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-3f3d-76db-b33b-3209be8d18b0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.4,
        "x": 0.06,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "Source: http://www.ericlinmd.com/back-vas-form.php; consultation call with expert.",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5928ddfd-f1a6-4cec-ac85-5cc08e491e23",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.85,
        "x": 0.06,
        "y": 0.09
      },
      "kind": "title",
      "text": "3. Trial investigators, KOL's, and ex-employees painted the SENZA pivotal study as a fraud",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "266836ac-8b40-49b2-b215-ccf863a30b5d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.35,
        "x": 0.06,
        "y": 0.04
      },
      "kind": "title",
      "text": "Scorpion Capital | Nevro (NYSE: NVRO)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cb1055cd-5cf5-4851-b81d-baedaf8631a9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.06,
        "y": 0.42
      },
      "kind": "title",
      "text": "Nevro's key European 24-month HF study",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "454cd4cd-c45d-47ce-8d04-34a3bf8b9526",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.45,
        "x": 0.51,
        "y": 0.42
      },
      "kind": "title",
      "text": "Comments by key US player in SENZA US pivotal trial",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6433d347-fa30-4ced-9dc2-fd0675127ad9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "f42abb1e-7cc3-410f-b849-2ed82c9b1512",
      "evidence": "The slide explicitly frames the company's clinical evidence as a 'fraud' by contrasting it with the testimony of the lead investigator.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 150,
      "from": 51,
      "beatId": "903c076a-f368-4ca1-844c-277874c1afb2",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "The Victory",
      "beatSlug": "overcoming-monster-the-victory",
      "evidence": "The deck presents a conclusion that Nevro's problems are insurmountable",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}